

Intercell AG

Document according to section 75a of the Austrian Stock Exchange Act (SEA) of mandatory announcements during the fiscal year 2008

Date	Type	Description	Source
16.01.2008	Ad-hoc announcement	Intercell Receives Manufacturer's Licence for Future Commercial Manufacturing of its Vaccine Against Japanese Encephalitis	www.intercell.com
19.01.2008	Disclosure according to section 174 (2) Stock Corporation Act	Disclosure regarding the authorization to issue convertible bonds	Wiener Zeitung
06.02.2008	Ad-hoc announcement	Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II	www.intercell.com
14.02.2008	Ad-hoc announcement	Vaccine formulated with Intercell's adjuvant IC31® part of a broader collaboration to fight Tuberculosis	www.intercell.com
27.02.2008	Ad-hoc announcement	Phase I für verbesserten Grippe-Impfstoff mit Adjuvans IC31® von Intercell abgeschlossen	www.intercell.com
29.02.2008	Ad-hoc announcement	Licensure application for Japanese Encephalitis vaccine submitted to Therapeutic Goods Administration (TGA) in Australia	www.intercell.com
03.03.2008	Ad-hoc announcement Q4 & full year results	Intercell announces Q4 and preliminary full-year 2007 results	www.intercell.com
15.04.2008	Ad-hoc announcement	Intercell's investigational vaccine against Japanese Encephalitis shows excellent safety and immunogenicity in Phase II trials in children	www.intercell.com
12.05.2008	Ad-hoc announcement	Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation	www.intercell.com
13.05.2008	Ad-hoc announcement Q1 results	Intercell AG announces Q1 2008 results and update on development programs	www.intercell.com

20.05.2008	AGM Invitation	Invitation for the Annual General meeting held on June 13, 2008	Wiener Zeitung
20.05.2008	Report according to sec.98 (3) and 159 (2) lit 3 Stock Corporations Act	Report of the Management Board on the grant of stock options to the members of the Supervisory Board	Wiener Zeitung
05.06.2008	Ad-hoc announcement	Intercell granted Early Termination of HSR Waiting Period for Iomai-Acquisition	www.intercell.com
13.06.2008	Ad-hoc announcement	Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31®	www.intercell.com
19.06.2008	Ad-hoc announcement	Licensure application for Japanese Encephalitis vaccine submitted to Canadian Division of Biologics and Genetic Therapies Directorate of Health	www.intercell.com
11.07.2008	Ad-hoc announcement	Iomai Acquisition granted clearance by US Authorities	www.intercell.com
12.07.2008	Report according to sec.171 (1) and 153 (4) Stock Corporations Act	Capital increase against in kind contribution and exclusion of subscription rights	Wiener Zeitung
14.07.2008	Publication according to section 4 and 5 Publication Ordinance (VöffVO)	Disclosure regarding disposal of 25,000 treasury shares in connection with the exercise of stock options	Euroadhoc (European distribution service)
01.08.2008	Ad-hoc announcement	Iomai shareholders approve acquisition by Intercell	www.intercell.com
05.08.2008	Ad-hoc announcement	Intercell AG closes Acquisition of Iomai Corporation	www.intercell.com
05.08.2008	Report according to 159 (2) lit 3 and sec.95 (6) and Stock Corporations Act	Report of the Management Board on the grant of stock options to employees	Wiener Zeitung

18.08.2008	Ad-hoc announcement Q2/H2 results	Intercell AG announces Q2/ H1 2008 results and gives update on business	www.intercell.com
21.08.2008	Ad-hoc announcement	US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis vaccine	www.intercell.com
28.08.2008	Ad-hoc announcement	Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine to prevent S. aureus infection	www.intercell.com
20.10.2008	Ad-hoc announcement	Intercell making strides towards imminent approval of its Japanese Encephalitis vaccine in the United States – Approvals in United States, Europe and Australia remain on track for 2008	www.intercell.com
11.11.2008	Ad-hoc announcement Q3 results	Intercell AG announces Q3 2008 results and updates on development programs	www.intercell.com
12.11.2008	Announcement according to section 93 subs. 2 SEA	Changes in shares of voting rights: V-Sciences Investment Pte Ltd reduced its share of the voting rights to less than 5 %	Euroadhoc (European distribution service)
04.12.2008	Report according to 159 (2) lit 3 and sec.95 (6) and Stock Corporations Act	Report of the Management Board on the grant of stock options to members of the management board and employees	Wiener Zeitung
10.12.2008	Ad-hoc announcement	USD 12.5 m funding for the development of Intercell's vaccine patch system for Pandemic Influenza from U.S. Department of Health and Human Services (HHS)	www.intercell.com
12.12.2008	Ad-hoc announcement	Australia first country to receive positive recommendation for Intercell's vaccine to prevent Japanese Encephalitis	www.intercell.com
15.12.2008	Ad-hoc announcement	Intercell receives CHMP positive opinion for the approval of IXIARO® in Europe – A vaccine against Japanese Encephalitis	www.intercell.com
19.12.2008	Ad-hoc announcement	Intercell update on technology partnerships: Intercell outlicenses Group B Streptococcus vaccine	www.intercell.com

22.12.2008	Announcement according to section 93 subs. 2 SEA	Changes in shares of voting rights: Deutsche Bank AG, together with its investment firms Deutsche Asset Management Investment GmbH, Deutsche Asset Management (Japan) Limited, Deutsche Investment Management Americas Inc., DWS Investment GmbH und DWS Investment S.A., Luxembourg, acquired a share in the voting rights of more than 5 %	Euroadhoc (European distribution service)
29.12.2008	Ad-hoc announcement	Product Development Update: Intercell starts Phase II clinical trial for Pseudomonas aeruginosa vaccine and FDA approval of IXIARO® expected in early 2009	www.intercell.com
30.12.2009	Announcement according to section 93 subs. 2 SEA	Announcement total number of voting rights: The total amount of voting rights was 47,234,603 by the end of the month December 2008	Euroadhoc (European distribution service)